A2A Appoints New AdvisorsA2A PharmaOct 2, 20191 min readDr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE
A2A TACC3 Program Clinical Progress in Womens CancersMay 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...
A2A co-founded biomea Fusion raises $56MBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...
Comments